Can-Fite BioPharma Ltd. (CANF)
USD 1.33
(-6.34%)
USD 1.33
(-6.34%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 39.99 Thousand USD | -35.49% |
| 2022 | 62 Thousand USD | -50.0% |
| 2021 | 124 Thousand USD | 85.07% |
| 2020 | 67 Thousand USD | -10.67% |
| 2019 | 75 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 0.0% |
| 2013 | - USD | 0.0% |
| 2012 | - USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | - USD | 0.0% |
| 2024 Q1 | - USD | -100.0% |
| 2023 Q4 | 39.99 Thousand USD | -21.57% |
| 2023 FY | 39.99 Thousand USD | -35.49% |
| 2023 Q1 | 48 Thousand USD | -22.58% |
| 2023 Q2 | 66 Thousand USD | 37.5% |
| 2023 Q3 | 51 Thousand USD | -22.73% |
| 2022 Q1 | 109 Thousand USD | -12.1% |
| 2022 Q4 | 62 Thousand USD | -16.22% |
| 2022 Q3 | 74 Thousand USD | -14.94% |
| 2022 FY | 62 Thousand USD | -50.0% |
| 2022 Q2 | 87 Thousand USD | -20.18% |
| 2021 Q1 | 55 Thousand USD | -17.91% |
| 2021 Q4 | 124 Thousand USD | 21.57% |
| 2021 Q3 | 102 Thousand USD | 50.0% |
| 2021 Q2 | 68 Thousand USD | 23.64% |
| 2021 FY | 124 Thousand USD | 85.07% |
| 2020 Q1 | 29 Thousand USD | -61.33% |
| 2020 Q2 | 58 Thousand USD | 100.0% |
| 2020 FY | 67 Thousand USD | -10.67% |
| 2020 Q3 | 49 Thousand USD | -15.52% |
| 2020 Q4 | 67 Thousand USD | 36.73% |
| 2019 Q1 | - USD | 0.0% |
| 2019 Q4 | 75 Thousand USD | 0.0% |
| 2019 Q2 | - USD | 0.0% |
| 2019 Q3 | - USD | 0.0% |
| 2019 FY | 75 Thousand USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 0.0% |
| 2014 FY | - USD | 0.0% |
| 2014 Q2 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 FY | - USD | 0.0% |
| 2013 Q4 | - USD | 0.0% |
| 2012 Q1 | - USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 495 Thousand USD | 91.919% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | 85.402% |
| Armata Pharmaceuticals, Inc. | 120.37 Million USD | 99.967% |
| Actinium Pharmaceuticals, Inc. | 2.11 Million USD | 98.107% |
| Azitra, Inc. | 885.94 Thousand USD | 95.485% |
| Chromocell Therapeutics Corporation | 1.26 Million USD | 96.847% |
| Calidi Biotherapeutics, Inc. | 7.23 Million USD | 99.447% |
| CEL-SCI Corporation | 13.57 Million USD | 99.705% |
| iBio, Inc. | 4.46 Million USD | 99.103% |
| Lineage Cell Therapeutics, Inc. | 2.95 Million USD | 98.645% |
| MAIA Biotechnology, Inc. | - USD | -Infinity% |
| Matinas BioPharma Holdings, Inc. | 3.55 Million USD | 98.875% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 98.357% |
| NovaBay Pharmaceuticals, Inc. | 2.74 Million USD | 98.54% |
| NanoViricides, Inc. | - USD | -Infinity% |
| Oragenics, Inc. | 312.7 Thousand USD | 87.209% |
| BiomX Inc. | 15.09 Million USD | 99.735% |
| BiomX Inc. | 15.09 Million USD | 99.735% |
| Protalix BioTherapeutics, Inc. | 26.28 Million USD | 99.848% |
| Palatin Technologies, Inc. | 590.33 Thousand USD | 93.224% |
| Scorpius Holdings, Inc. | 14.04 Million USD | 99.715% |